Novartis Investigative Site

Padova, Veneto 35128

0 studies enrolling now · 5 studies all time

What they study most

Melanoma, Melanoma and Brain Metastases, Purpura, Thrombocytopaenic, Idiopathic

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma — Completed
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain — Completed
• EXTEND (Eltrombopag Extended Dosing Study) — Completed